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Sgeneration WATCHMAN LAA closure device. Of the 36 patients, the new device
was implanted in 34 (94.4%). In two patients (5.6%), device closure was attempted
but unsuccessful due to an unfavorable LAA anatomy (early separation into multiple
lobes in one and acute LAA angulation in the second). In these cases closure was
performed successfully with a different closure system. Though in eight patients
partial and in fourteen full recaptures were needed prior to ﬁnal release, there was no
pericardial effusion. Mean procedural time was 50  45 minutes. No device-related
adverse events occurred during the procedure and accurate device placement was
achieved in all implanted patients. During the follow-up of 12 months, three
ischemic strokes (8.3%), one hemorrhage stroke (2.7%), one TIA (2.7%) and three
deaths (8.7%) occurred. Device-associated thrombus formation was seen in one
patient (2.7%) at the six-month follow-up treated with low molecular weight
heparin.
Conclusions: LAA closure with the newer (fourth) generation WATCHMAN device
is feasible and safe. The atraumatic distal end may reduce the incidence of pericardial
effusion during implantation.
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Background: Recent study results present left atrial appendage (LAA) occluders as
an alternative to oral anticoagulation for stroke prevention in patients with atrial
ﬁbrillation. Several devices with different designs (speciﬁcally different anchoring
methods and diameters) are being tested in clinical and animal trials with good results.
Device anchoring and achieving sufﬁcient seal remain challenges, considering the
diverse morphologies of the LAA, but must be achieved in order to prevent residual
ﬂow and possible associated thrombotic events. There are currently no standard
guidelines or norms for in-vitro assessment and comparability of LAA occluders and
their function.
Methods: In order to design a test system for the in-vitro assessment of LAA
occluder function, a design study and review of literature and CT-data were per-
formed. Additionally, anatomical studies on LAAs of porcine hearts were performed
to better incorporate the surface structure and mechanical properties into the test
setup.
Results: A modular in-vitro test system with the possibility of integrating exact
physiological models of the LAA was developed. The system allows for integration
and exchange of different LAA morphologies cast from silicone or native animal
anatomies and has the possibility to assess permeability, seal and anatomical ﬁt of
LAA occluders.
Conclusions: Standardized tests are essential during the establishment of novel device
based therapies, to ensure comparability and the fulﬁllment of basic requirements. The
in-vitro test setup for LAA occluders presented here allows for assessment and
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procedures at the AK St. Georg, Hamburg
Thomas Thielsen1, Christian Frerker1, Felix Kreidel1, Hannes Alessandrini1,
Marco Marzullo1, Karl-Heinz Kuck1, Ulrich Schaefer1
1Asklepios Klinik St. Georg, Hamburg, Germany
Background: Hemodynamic changes after MitraClip procedure are rarely described
till today. Aim of this work was to improve the understanding of the acute hemo-
dynamic effects.
Methods: Till today more than 330 Patients have been treated with the MitraClip
System at the AK St. Georg in Hamburg. Hemodynamics have been evaluated with
Swan Ganz catheterization and thermodilution method directly before and after
Clipping. The functional result was assessed 6 weeks, 6 months and 12 months after
the MitraClip procedure.B212 JACC Vol 62/18/Suppl B j October 27–NovemberResults: 314 out of 330(95.2%) patients could be treated successfully (MR post 2).
30 day mortality was 7%. MR was reduced signiﬁcantly from 3.0(0.3) to 1.1(1.1)
(p<0.001), needing an average of 1.4 Clips(0.6). Cardiac output(CO) increased
from 3.7l/min(1.1) to 4.7l/min(1.3) directly after the procedure (p<0.001). Stroke
volume(SV) increased from 62.4ml(18.7) to 80.7ml(26.9) (p<0.001). Systolic
pulmonary artery pressure (PAPs) increased slightly from 39.9mmHg(12.5) to
42.2mmHg(12.2) (p<0.05). Wedge pressure (PCWP, mean) fell from
16.8mmHg(7.8) before to 15.7mmHg(6.5) post MitraClip (p<0.05). Left atrial
pressure (LA, mean) was reduced signiﬁcantly (p<0.001) from 16.1mmHg(6.9) to
13.2mmHg(6.1). Grade of dyspnea by NYHA fell signiﬁcantly as well (3.2(0.5)
baseline, 2.1(0.7) after 6 months and 2.2(0.6) after 12 months), p<0.001. Grade of
MR assessed by echo was reduced stable and signiﬁcantly from 3.1(0.3) before to
1.1(0.6) directly after and 1.8(0.7) after 6 months, p<0.001.
Conclusions: The MitraClip procedure shows a stable reduction of MR combined
with a stable improvement of the clinical symptom dyspnea. We’ve shown that this
non open chest treatment of MR improves the CO and SV of up to 27% while
reducing LA pressure signiﬁcantly. If these ﬁndings have a prognostic impact is part
of running investigation.
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Background: In Europe, MitraClip (MC) therapy for signiﬁcant mitral regurgitation
(MR) is increasingly being performed, particularly in elderly patients at high surgical
risk. Outcomes emphasizing differences between men and women are lacking. We
present a high-volume single-center retrospective analysis of outcomes according to
gender.
Methods: By 01/2013, 361 consecutive patients (75  9 years, 227 men [M; 63%],
134 women [F; 37%]) with MR 3+/4+ had undergone MC therapy at the University
Heart Center Hamburg. All patients were adjudicated by heart team consensus as not
amenable to surgery.
Results: Baseline conditions were signiﬁcantly more adverse in M than in F, with
higher log. EuroSCORE, lower LVEF, and higher prevalence of cardiomyopathy,
hypercholesterolemia, diabetes, coronary artery disease, renal failure, and functional
MR in the former. Procedures were successful (discharge MR 2+) in 207 M (91%)
and 118 F (88%, p¼NS). Follow-up information was available in 205 M (90%) and
116 F (87%) at a median of 12.7 (range, 0.3-41) and 13.6 (0.4-39) months, respec-
tively (p¼NS). No signiﬁcant differences in the prevalence of MR 2+ and of NYHA
functional class II were observed at 12 months (MR: M 91%, F 85%; NYHA: M
60%, F 50%) and 24 months (MR: M 91%, F 80%; NYHA: M 62%, F 49%). Overall,
cumulative survival was not different between M and F (p[logrank]¼0.12), but
survival curves diverged signiﬁcantly in favor of F after 12 months (p¼0.03 by
landmark analysis). Independent predictors of death on multivariate Cox regression
analysis were renal failure and MC failure in M, yet renal failure and dilated
cardiomyopathy in F. Rehospitalizations were frequent (M 54% and F 41% at 18
months), but not signiﬁcantly different between M and F. MC failure was predictive of
rehospitalizations in both genders.
Conclusions: MC therapy appears to be equally effective, acutely as well as in the
long term, in M and F at high surgical risk. Increased mortality after 1 year in M is
likely related to higher comorbidity and poorer LV function and requires further study.
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Background: The aim of this study is to investigate the predictors of quality of life
(QoL) restoration 1 year after MitraClip implantation in heart failure patients with
FMR in our single center experience.
Methods: From October 2008, 109 consecutive patients with FMR underwent
MitraClip implantation (mean age 699 years). FMR was ischemic in 75%. All
patients underwent standardized assessment of mitral valve anatomy and functional
status. Preprocedural QoL was assessed by Minnesota Living with Heart Failure
Questionnaire (MLHFQ). Logistic EuroScore was 2216%; 82% pts were in NYHA
class III-IV. Mean EF was 2811%; LVEDD was 688 mm. A cut-off of 14 points
with MLHFQ was used to deﬁne QoL restoration 1 year after the procedure (corre-
sponding to the mean MLHFQ observed in a NYHA I-II heart failure Italian pop-
ulation with mean age of 61 years).1, 2013 j TCT Abstracts/POSTER/Mitral Valve Disease and Treatment
